Absci Corporation (ABSI)
NASDAQ: ABSI · Real-Time Price · USD
8.30
-0.10 (-1.19%)
At close: Aug 6, 2026, 4:00 PM EDT
8.35
+0.05 (0.60%)
Pre-market: Aug 7, 2026, 5:38 AM EDT
Absci Employees
Absci had 140 employees as of December 31, 2025. The number of employees decreased by 17 or -10.83% compared to the previous year.
Employees
140
Change (1Y)
-17
Growth (1Y)
-10.83%
Revenue / Employee
$13,114
Profits / Employee
-$845,971
Market Cap
1.41B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 140 | -17 | -10.83% | 140 | 0 |
| Dec 31, 2024 | 157 | 1 | 0.64% | 156 | 1 |
| Dec 31, 2023 | 156 | -37 | -19.17% | 155 | 1 |
| Dec 31, 2022 | 193 | -19 | -8.96% | 193 | 0 |
| Dec 31, 2021 | 212 | 110 | 107.84% | 211 | 1 |
| Sep 30, 2021 | 207 | 105 | 102.94% | 207 | 0 |
| Jun 30, 2021 | 169 | - | - | 169 | 0 |
| Mar 31, 2021 | 102 | - | - | 102 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Ascentage Pharma Group International | 767 |
| Vir Biotechnology | 367 |
| Xencor | 260 |
| Monte Rosa Therapeutics | 187 |
| Innoviva | 159 |
| Maze Therapeutics | 141 |
| MoonLake Immunotherapeutics | 130 |
| ORIC Pharmaceuticals | 104 |
ABSI News
- 16 days ago - Absci management to meet virtually with KeyBanc - TheFly
- 23 days ago - Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026 - GlobeNewsWire
- 4 weeks ago - Absci director buys $149K in common stock - TheFly
- 5 weeks ago - Healthcare stocks have become a haven for investors ditching tech - Market Watch
- 6 weeks ago - Absci price target raised to $10 from $4.10 at Morgan Stanley - TheFly
- 6 weeks ago - Absci price target raised to $16 from $8 at H.C. Wainwright - TheFly
- 6 weeks ago - Absci prices 13.5M shares at $7.41 in public offering - TheFly
- 6 weeks ago - Absci reports Phase 1 data from human trial of ABS-201 - TheFly